Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PEARL1 (PCDH eRNA associated with R-loop formation 1) is a long non-coding RNA, specifically an enhancer RNA (eRNA), transcribed from the HS5-1 enhancer region within the protocadherin α (Pcdhα) gene cluster[1][3][4]. It functions locally in the genome (in cis) to form R-loops, which are RNA–DNA hybrids that facilitate chromatin looping between distal enhancers and their variable target promoters. This looping is critical for the stochastic, cell-type–specific expression of protocadherin α genes, especially in brain tissue, where these proteins contribute to neural identity. The role of PEARL1 is mechanistic and regulatory rather than as a classical therapeutic target such as a receptor, enzyme, or transporter. There are no known small-molecule drugs or therapeutic antibodies targeting PEARL1, and its primary biological significance lies in gene expression regulation and the three-dimensional organization of chromatin domains in neural tissue[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PCDH eRNA associated with R-loop formation 1 (PEARL1).